In a report released today, Difei Yang from Mizuho Securities maintained a Buy rating on Xeris Pharmaceuticals (XERS), with a price target of $9.00. The company’s shares closed last Thursday at $3.24, close to its 52-week low of $2.45.
According to TipRanks.com, Yang has 0 stars on 0-5 stars ranking scale with an average return of -6.8% and a 35.2% success rate. Yang covers the Healthcare sector, focusing on stocks such as Freeline Therapeutics Holdings, Sarepta Therapeutics, and Magenta Therapeutics.
Currently, the analyst consensus on Xeris Pharmaceuticals is a Strong Buy with an average price target of $8.00, a 138.1% upside from current levels. In a report issued on May 13, RBC Capital also maintained a Buy rating on the stock with a $10.00 price target.
See today’s analyst top recommended stocks >>
Based on Xeris Pharmaceuticals’ latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $8.05 million and GAAP net loss of $18.41 million. In comparison, last year the company earned revenue of $1.68 million and had a GAAP net loss of $29.18 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Xeris Pharmaceuticals, Inc.is a pharmaceutical company, which develops and commercializes ready-to-use, liquid-stable injectables. It offers XeriSol™ and XeriJect™ formulation technologies. The company was founded by Steven Prestrelski and John Kinzell in 2005 and is headquartered in Austin, TX.
